(Q40960891)

25 September 2017

1 reference

title

Past, present, and future of antimicrobial agents (English)

1 reference

25 September 2017

R C Moellering

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

99

1 reference

25 September 2017

issue

6A

1 reference

25 September 2017

page(s)

11S-18S

1 reference

Antimicrobial properties of tea (Camellia sinensis L.).

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Screening of natural products for antimicrobial agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

6-APA and the development of the β-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

An Enzyme from Bacteria able to Destroy Penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Expression of antibiotic resistance genes in the integrated cassettes of integrons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Recovery of resistance (R) factors from a drug-free community.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

How the pharmaceutical industry brings an antibiotic drug to market in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

RP 59500: a proposed mechanism for its bactericidal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Active efflux mechanisms for antimicrobial resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

In vitro activities of two glycylcyclines against gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Genetics and mechanisms of glycopeptide resistance in enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Inhibition of peptidoglycan biosynthesis by ramoplanin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Development of novel inhibitor probes of DNA polymerase III based on dGTP analogs of the HPUra type: base, nucleoside and nucleotide derivatives of N2-(3,4-dichlorobenzyl)guanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Stationary phase induction in Escherichia coli--new targets for antimicrobial therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Selection of bacterial virulence genes that are specifically induced in host tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

Diagnosing bacterial infectious diseases in one hour: an essential upcoming revolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980279-4

10.1016/S0002-9343(99)80279-4

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference